Drug Approval | January 09, 2026
BeOne Medicines wins first-in-world nod for Sonrotoclax in China
The approval is backed by data showing deep, durable responses and manageable tolerability
The approval is backed by data showing deep, durable responses and manageable tolerability
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Elanco expects Befrena to launch in the US in the first half of 2026
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The partnership also sets the stage for broader collaboration on rare disease treatments
Subscribe To Our Newsletter & Stay Updated
